NCM · Biotechnology

Outlook Therapeutics, Inc. (OTLK) Stock

$1.17 -16.73% NCM: OTLK Healthcare

Outlook Therapeutics, Inc. is a biopharmaceutical company in the advanced stages of clinical development, focused on inventing and bringing to market monoclonal antibody treatments for various eye conditions.

Valuation

MetricValue
Price$1.17
Market Cap$48.13M
P/E Ratio-1.03
P/B Ratio-3.97
P/S Ratio173.51
EPS (TTM)$-1.79
52-Week High$3.39
52-Week Low$0.16
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE178.08%
ROA-278.44%
ROCE356.50%
Gross Margin-6700.00%
Operating Margin-6700.00%
Net Margin-0.05%
Debt/Equity-0.94
Current Ratio0.37

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$1.0M
Operating Profit$-52.0M$-63.0M$-53.0M$-72.0M$-67.0M
Net Profit$-53.0M$-66.0M$-59.0M$-75.0M$-62.0M
EPS$-6.96$-6.23$-4.72$-4.06$-1.79
Op Margin————-4744.3%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$23.0M$29.0M$32.0M$29.0M$19.0M
Total Liabilities$18.0M$20.0M$47.0M$102.0M$51.0M
Cash$14.0M$17.0M$23.0M$15.0M$8.0M
Borrowings$12.0M$11.0M$36.0M$30.0M$30.0M

Latest News

Outlook Therapeutics Registers 17.3 Million Shares for Resale MT Newswires · Jul 17, 2026 Outlook Therapeutics (OTLK) Gets July 29 PDUFA Date for LYTENAVA Insider Monkey · Jul 14, 2026 Outlook Therapeutics Regains Nasdaq Compliance MT Newswires · Jun 29, 2026 OTLK Stock Up 35% as FDA Accepts Resubmitted Eye Drug BLA for Review Zacks · Jun 17, 2026 Outlook Therapeutics (OTLK) Stock After FDA Review Win Is The Valuation Case Already Priced In Simply Wall St. · Jun 16, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-54.0M$-57.0M$-43.0M$-69.0M$-52.0M
Investing Cash Flow$0$0$0$0$0
Financing Cash Flow$4.0M$0$-1.0M$0$0
Net Cash Flow$2.0M$3.0M$6.0M$-8.0M$-7.0M
Free Cash Flow$-54.0M$-57.0M$-43.0M$-69.0M$-52.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.06
EV / EBITDA-1.02
FCF Yield-108.04%
Quick Ratio0.30
Interest Coverage-193.21
Return 1Y-30.84%
Return 3Y-95.24%
Return 5Y-96.50%

Ownership

Insiders Held17.42%
Institutions Held6.94%
Institutions Float Held8.40%
Institutional HolderSharesReport Date
Armistice Capital, LLC4,168,0002026-03-31
Vanguard Capital Management LLC1,967,1602026-03-31
Geode Capital Management, LLC603,6062026-03-31
Gilpin Wealth Management, LLC600,1622026-03-31
Commonwealth Equity Services, LLC470,0002026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
COEPCoeptis Therapeutics Holdings, Inc. $10.99 -8.57% -4.45 $38.62M 0.00%
CUE $32.57 +1.40% -4.05 $85.59M 0.00%
EQ $2.57 +3.21% -5.28 $91.29M 0.00%
HOWL $0.40 -3.04% -0.33 $19.54M 0.00%
IOBTIO Biotech, Inc. $0.01 -27.59% -0.01 $885690 0.00%

About Outlook Therapeutics, Inc.

Outlook Therapeutics, Inc. is a biopharmaceutical company in the advanced stages of clinical development, focused on inventing and bringing to market monoclonal antibody treatments for various eye conditions. Its flagship drug candidate, ONS-5010, is an ophthalmic formulation of bevacizumab currently undergoing crucial Phase III clinical trials. This investigational product is being evaluated for its potential to treat wet age-related macular degeneration and other serious retinal diseases. The company has forged strategic collaboration and licensing agreements with several partners, including IPCA Laboratories Limited, Laboratorios Liomont, S.A. de C.V., BioLexis Pte. Ltd., and Zhejiang Huahai Pharmaceutical Co., Ltd. Incorporated in 2010, the firm was formerly known as Oncobiologics, Inc., changing its name to Outlook Therapeutics, Inc. in November 2018. Its corporate base is located in Iselin, New Jersey.

Outlook Therapeutics, Inc. is led by CEO Robert Charles Jahr, employs 23 people, headquartered in US, publicly traded since 2016.

Outlook Therapeutics, Inc. (OTLK) stock trades at $1.17 with a market capitalization of $48.13M. The stock is valued at a price-to-earnings (P/E) ratio of -1.03, price-to-book of -3.97, price-to-sales of 173.51. Over the past 52 weeks the stock has ranged between $0.16 and $3.39, and currently trades 65.5% below its 52-week high.

On profitability, Outlook Therapeutics, Inc. generates a return on equity (ROE) of 178.08% — well above the market average, a sign of a high-quality business, return on capital employed of 356.50%, an operating margin of -6700.00%, a net profit margin of -0.05%.

Official website: www.outlooktherapeutics.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides